Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Atossa Genetics Inc (ATOS)

Atossa Genetics Inc (ATOS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Atossa Therapeutics Announces Clinical Progress

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced...

ATOS : 1.5000 (+44.23%)
New Research: While Mid-Size Banks Gain Efficiencies Through Scale, They Come Up Short on Delivery of Digital and Automated Services

Cornerstone Advisors today released the Cornerstone Performance Report for Banks 2019, the thirteenth in a series of benchmarking studies published by the firm. According to the report's findings, despite...

ATOS : 1.5000 (+44.23%)
New COVID-19 HOPE Clinical Trial Recommendations Introduced Today May Reduce or Eliminate Mechanical Ventilation for Coronavirus Patients

Crucial life-saving initiative led by Dr. Steven Quay for clinical trials on the safety and efficacy of a combination of FDA-approved drugs (nebulized Heparin-N-acetylcysteine in COVID-19 Patients by Evaluation...

ATOS : 1.5000 (+44.23%)
Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced...

ATOS : 1.5000 (+44.23%)
Atossa Therapeutics Announces Upcoming Meeting with FDA

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today that...

ATOS : 1.5000 (+44.23%)
Atossa Therapeutics, Inc. Files for Swedish Regulatory Approval to Initiate a Phase 2 Study of Oral Endoxifen to Reduce Mammographic Breast Density

Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that...

ATOS : 1.5000 (+44.23%)
Atossa Therapeutics, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that...

ATOS : 1.5000 (+44.23%)
Interview with Atossa Therapeutics' Kyle Guse On World Cancer Day "Transforming Breast Cancer Treatment"

Every February 4th is , the global uniting initiative led by the Union for International Cancer Control (UICC). By raising worldwide awareness, improving education and catalyzing personal, collective,...

ATOS : 1.5000 (+44.23%)
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2020

Atossa Therapeutics, Inc. (Nasdaq:ATOS) today issued the following letter from Dr. Steven C. Quay, President and CEO, to Atossa shareholders:

ATOS : 1.5000 (+44.23%)
Atossa Genetics Announces Corporate Name Change to Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that...

ATOS : 1.5000 (+44.23%)
Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that it...

ATOS : 1.5000 (+44.23%)
Atossa Genetics to Present at the LD Micro 12th Annual Main Event on December 10, 2019

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle...

ATOS : 1.5000 (+44.23%)
Atossa Genetics Announces Third Quarter 2019 Financial Results and Provides Company Update

Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial...

ATOS : 1.5000 (+44.23%)
Atossa Genetics to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle...

ATOS : 1.5000 (+44.23%)
Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, and The Dr. Susan Love Research...

ATOS : 1.5000 (+44.23%)
Interview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over Gynecomastia

SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2019 / Recently, Steven Quay MD, Ph.D., Founder, Chairman and CEO of Atossa Genetics Inc. (NASDAQ:), a clinical-stage biopharmaceutical company developing novel...

ATOS : 1.5000 (+44.23%)
JNJ : 139.76 (+4.17%)
Interview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over Gynecomastia

SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2019 / Recently, Steven Quay MD, Ph.D., Founder, Chairman and CEO of Atossa Genetics Inc. (NASDAQ:), a clinical-stage biopharmaceutical company developing novel...

ATOS : 1.5000 (+44.23%)
JNJ : 139.76 (+4.17%)
Atossa Genetics Announces Preliminary Results from Phase 1 Study of Modified-Release Tablet Oral Endoxifen

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today reported preliminary...

ATOS : 1.5000 (+44.23%)
Atossa Genetics to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle...

ATOS : 1.5000 (+44.23%)
Atossa Genetics Announces Completion of Enrollment and Dosing in Phase 1 Clinical Trial of New Proprietary Modified-Release Oral Endoxifen Tablet

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that all...

ATOS : 1.5000 (+44.23%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS +6.62 , SEDG +10.67 , THC +1.63 , TER +6.34 , LITE +7.94
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar